It’s been a busy year for everyone and it’s almost over. We at InVitria wanted to take a moment to recap some of the white papers, webinars, and other publications that you may have missed.
Revolutionizing T Cell Immunotherapies
Eliminate Serum & Blood-Derived Components from Your Immunotherapy Applications
Production of Adenoviral Associated Viral Vectors (AAV)
Adenoviral associated viral (AAV) vectors used in gene therapy have received notable attention considering the recent clinical successes. Learn more about the successes in our white paper.
The global leader in the production of blood-free components, supplements, and media to facilitate the approval of life changing medicines.
InVitria’s portfolio of chemically defined blood-free products enables development and production of novel therapeutics without use of any blood-derived components.
Click on the application of interest to find out how our products set the new standards in biologics manufacturing.
InVitria offers a suite of recombinant protein products, each of which is completely free of animal or human components and produced in a scalable, non-mammalian recombinant expression system at an ISO9001:2015 certified facility in Kansas, USA.
InVitria is the leading brand of custom media formulations for gene therapy, cell therapy, vaccine & antibody production, and related culturing applications. Contact us to discuss your cell culture needs. Let us do the heavy lifting!
- Blood-Free & Chemically Defined
- High Performance
- Reliable Supply Chain
- Faster Time to Market
Select the cell line or an application of interest and discover more information relevant to your work.
- Decreased variability in cell culture media.
- Accelerated gene therapy research.
- Improved scalability & increased speed of gene therapy manufacturing.
- Reduced cost in time and resources for manufacturing.